Global CRISPR Cas9 Market Opportunity & Clinical Trials Outlook 2029
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
Global CRISPR Cas9 Market Opportunity & Clinical Trials Outlook 2029 Report Offering:
With respect to KuicK Research statistics, we anticipate to perceive the first wave of CRISPR/Cas9 therapies receiving regulatory approvals over and above entering the market in upcoming 5 years due to the fact that as these therapies demonstrate their effectiveness in addition to safety in real-world settings, they will pave the way for broader acceptance and application of CRISPR/Cas9 based treatments. Coupled with this, the potential applications of this groundbreaking gene-editing technology are expected to expand dramatically beyond genetic disorders and cancers and will be utilized to cure cardiovascular, neurodegenerative together with CNS diseases as evident from rising preclinical as well as clinical studies, touching fundamentally every area of medicine and biotechnology.
Until now, the clinical pipeline for global CRISPR/Cas9 therapy is up surging year by year with multiple therapies have entered into clinical trials and other CRISPR/Cas9 candidates are lately in the preclinical stage. Many of ongoing CRISPR/Cas9 clinical trials have reached late stage of development and it is predicable that they will penetrate into the market in the imminent 5-7 years. For instance, Intellia Therapeutics has begun a phase III, multinational, multicenter, double-blind, placebo-controlled study is ongoing which aims to evaluate the efficacy and safety of a single dose of NTLA-2001, a CRISPR/Cas9 therapy, compared to placebo in participants with transthyretin amyloidosis with cardiomyopathy (ATTR-CM). The study (MAGNITUDE) was begun in December 2023 and is anticipated to be complete by April 2028 coupled with clenches an enrollment of 765 participants.
Just as importantly, the over-all market for CRISPR/Cas9 therapies is estimated to grow substantively and will become a multi-billion-dollar industry over the impending eons, driven by the snowballing number of preclinical and clinical trials, the likely regulatory approvals, in conjugation with the increase of indications. Currently, the US dominates the CRISPR/Cas9 sphere in terms of research and development activities, but EU is correspondingly far-sighted momentous evolution in this field.
As well as, the current approved CRISPR/Cas9 therapy; Casgevy, developed by CRISPR Therapeutics and Vertex Pharmaceutical, is launched into the market at an average cost of roughly US$ 2 Million per single course of treatment according to Casgevy developer company SEC filings. Additionally, the anticipated high prices of these therapies, justified by their potential curative nature, are expected to further drive significant market growth in terms of revenue, even with relatively small patient populations.
As a final point, all elucidations aforesaid epitomize that the global CRISPR/Cas9 therapy is growing at a trailblazing gait and is predictable to multiply additional in the forthcoming 10 years. The expanding clinical application as well as together with indication of CRISPR/Cas9, mounting preclinical and clinical trials, rise in technological advancement, presences of key players like Intellia Therapeutics, CRISPR Therapeutics, Editas Medicine, TransCode Therapeutics and many more, combination studies of CRISPR/Cas9 with other therapies coupled with augment in investment, collaborations and government bestow are driving the market penetration, offering opportunism to pharma and biotech companies in future.
Global CRISPR Cas9 Market Opportunity & Clinical Trials Outlook 2029 Report Offering:
- Global & Regional: Commercial & Clinical Outlook
- Global CRISPR-Cas9 Therapy Clinical Trials By Company, County, Indication & Phase
- Number Of CRISPR-Cas9 Therapies In Trials: > 25 Therapies
- Approved CRISPR-Cas9 Therapy: Casgevy (Exagamglogene Autotemcel) Therapy Clinical Insight
- Approved CRISPR-Cas9 Therapy Pricing & Dosing Analysis
- Technology Platforms For Advancing CRISPR-Cas9 Therapy
- Delivery Methodologies For CRISPR-Cas9
- Competitive Landscape
With respect to KuicK Research statistics, we anticipate to perceive the first wave of CRISPR/Cas9 therapies receiving regulatory approvals over and above entering the market in upcoming 5 years due to the fact that as these therapies demonstrate their effectiveness in addition to safety in real-world settings, they will pave the way for broader acceptance and application of CRISPR/Cas9 based treatments. Coupled with this, the potential applications of this groundbreaking gene-editing technology are expected to expand dramatically beyond genetic disorders and cancers and will be utilized to cure cardiovascular, neurodegenerative together with CNS diseases as evident from rising preclinical as well as clinical studies, touching fundamentally every area of medicine and biotechnology.
Until now, the clinical pipeline for global CRISPR/Cas9 therapy is up surging year by year with multiple therapies have entered into clinical trials and other CRISPR/Cas9 candidates are lately in the preclinical stage. Many of ongoing CRISPR/Cas9 clinical trials have reached late stage of development and it is predicable that they will penetrate into the market in the imminent 5-7 years. For instance, Intellia Therapeutics has begun a phase III, multinational, multicenter, double-blind, placebo-controlled study is ongoing which aims to evaluate the efficacy and safety of a single dose of NTLA-2001, a CRISPR/Cas9 therapy, compared to placebo in participants with transthyretin amyloidosis with cardiomyopathy (ATTR-CM). The study (MAGNITUDE) was begun in December 2023 and is anticipated to be complete by April 2028 coupled with clenches an enrollment of 765 participants.
Just as importantly, the over-all market for CRISPR/Cas9 therapies is estimated to grow substantively and will become a multi-billion-dollar industry over the impending eons, driven by the snowballing number of preclinical and clinical trials, the likely regulatory approvals, in conjugation with the increase of indications. Currently, the US dominates the CRISPR/Cas9 sphere in terms of research and development activities, but EU is correspondingly far-sighted momentous evolution in this field.
As well as, the current approved CRISPR/Cas9 therapy; Casgevy, developed by CRISPR Therapeutics and Vertex Pharmaceutical, is launched into the market at an average cost of roughly US$ 2 Million per single course of treatment according to Casgevy developer company SEC filings. Additionally, the anticipated high prices of these therapies, justified by their potential curative nature, are expected to further drive significant market growth in terms of revenue, even with relatively small patient populations.
As a final point, all elucidations aforesaid epitomize that the global CRISPR/Cas9 therapy is growing at a trailblazing gait and is predictable to multiply additional in the forthcoming 10 years. The expanding clinical application as well as together with indication of CRISPR/Cas9, mounting preclinical and clinical trials, rise in technological advancement, presences of key players like Intellia Therapeutics, CRISPR Therapeutics, Editas Medicine, TransCode Therapeutics and many more, combination studies of CRISPR/Cas9 with other therapies coupled with augment in investment, collaborations and government bestow are driving the market penetration, offering opportunism to pharma and biotech companies in future.
1. SYNOPSIS TO CRISPR-CAS9 THERAPY
1.1 Overview
1.2 Approved CRISPR-Cas9 Therapies
2. DELIVERY METHODS FOR CRISPR-CAS9
2.1 Delivery of CRISPR-Cas9 Components Through Physical Methods
2.1.1 Microinjection
2.1.2 Electroporation
2.1.3 Hydrodynamic Delivery
2.2 Delivery of CRISPR-Cas9 Components through Viral Vectors
2.2.1 Adeno-Associated Virus (AAV)
2.2.2 Lentivirus & Adenovirus
2.3 Delivery of CRISPR-Cas9 Components through Non-Viral Vectors (Biomaterials)
2.3.1 Liposomes
2.3.2 Gold Nanoparticles
2.3.3 DNA Nanoclew
3. CRISPR-CAS9: A HOME TO VARIETY OF APPLICATIONS
3.1 Advantages Accompanying CRISPR-Cas9 Technology
3.2 CRISPR-Cas9 Comparison with other Genome Editing Tools
4. GLOBAL CRISPR-CAS9 THERAPY CLINICAL TRIALS OVERVIEW
4.1 By Company
4.2 By Country
4.3 By Indication
4.4 By Phase
4.5 By Priority Status
5. GLOBAL CRISPR-CAS9 THERAPY CLINICAL TRIALS BY COMPANY, COUNTY, INDICATION & PHASE
5.1 Research
5.2 Preclinical
5.3 Phase I
5.4 Phase I/II
5.5 Phase II
6. APPROVED CRISPR - CAS9 THERAPY: CASGEVY (EXAGAMGLOGENE AUTOTEMCEL) THERAPY CLINICAL INSIGHT
7. APPROVED CRISPR-CAS9 THERAPY - OVERVIEW, PRICING & DOSING ANALYSIS
7.1 Casgevy (Exagamglogene Autotemcel)
7.1.1 Overview
7.1.2 Pricing & Dosing
8. GLOBAL CRISPR-CAS9 THERAPY CURRENT MARKET TREND & DEVELOPMENTS
8.1 Current Market Outline
8.2 Future Market Outlook
9. CRISPR-CAS9 THERAPY MARKET TREND ANALYSIS BY REGION
9.1 US
9.2 UK
9.3 EU
9.4 China
9.5 Japan
9.6 South Korea
10. CRISPR-CAS9 THERAPY MARKET OPPORTUNITIES & CLINICAL TRIAL STATISTICS: BY INDICATIONS
10.1 Inherited Blood Disorders
10.2 Genetic Disorders
10.3 Cancer
10.4 Autoimmune & Inflammatory Disorders
10.5 Microbial Infections
10.6 Cardiovascular Illnesses
10.7 Eye Disorders, Brain Diseases, Metabolic Illness & Other Conditions
11. COMBINATION APPROACHES FOR CRISPR-CAS9 THERAPY
12. PLATFORMS FOR ADVANCING CRISPR-CAS9 THERAPY
12.1 CRISPR-GNDM Modalis Therapeutics Platform
12.2 Intellia Therapeutics - Modular Platform
12.3 Editas Medicine CRISPR Gene Editing Platform
12.4 CRISPR-Cas9 Genome Editing Technology – ERS Genomics
12.5 CRISTARS Gene Editing Technology Innovation Platform- BRL Medicine
12.6 Gene Editing-BDmRNA Platform Shanghai BDgene
12.7 Kamau Therapeutics Next-Generation Gene Editing Platform
12.8 Excision BioTherapeutics CRISPR Gene Editing Technology
13. GLOBAL CRISPR-CAS9 THERAPY MARKET DYNAMICS
13.1 Market Drivers
13.2 Market Achilles Heels
14. COMPETITIVE LANDSCAPE
14.1 4D Molecular Therapeutics
14.2 Arbor Biotechnologies
14.3 ASC Therapeutics
14.4 C4U Corporation
14.5 Casebia Therapeutics
14.6 CRISPR Therapeutics
14.7 Editas Medicine
14.8 Intellia Therapeutics
14.9 Nkarta Therapeutics
14.10 Vertex Pharmaceuticals
Table 1-1: Global - Approved CRISPR-Cas9 Therapies
Table 9-1: US – Ongoing CRISPR-Cas9 Clinical Trials
Table 9-2: CRISPR-Cas9 Candidates Granted FDA Designations
Table 9-3: EU – Ongoing Clinical Trials for CRISPR/Cas9-based Therapeutics, July’2024
Table 9-4: ERS Genomics – Collaborations
Table 10-1: Ongoing CRISPR-Cas9 Clinical Trials for Inherited Blood Disorders
Table 10-2: Ongoing CRISPR-Cas9 Clinical Trials for Cancer Disorders
Table 10-3: Collaboration Deals For Cancer CRISPR-Cas9 Therapy, July 2024
Table 11-1: Ongoing Preclinical & Clinical trials for Combination of CRISPR-Cas9 Therapy
1.1 Overview
1.2 Approved CRISPR-Cas9 Therapies
2. DELIVERY METHODS FOR CRISPR-CAS9
2.1 Delivery of CRISPR-Cas9 Components Through Physical Methods
2.1.1 Microinjection
2.1.2 Electroporation
2.1.3 Hydrodynamic Delivery
2.2 Delivery of CRISPR-Cas9 Components through Viral Vectors
2.2.1 Adeno-Associated Virus (AAV)
2.2.2 Lentivirus & Adenovirus
2.3 Delivery of CRISPR-Cas9 Components through Non-Viral Vectors (Biomaterials)
2.3.1 Liposomes
2.3.2 Gold Nanoparticles
2.3.3 DNA Nanoclew
3. CRISPR-CAS9: A HOME TO VARIETY OF APPLICATIONS
3.1 Advantages Accompanying CRISPR-Cas9 Technology
3.2 CRISPR-Cas9 Comparison with other Genome Editing Tools
4. GLOBAL CRISPR-CAS9 THERAPY CLINICAL TRIALS OVERVIEW
4.1 By Company
4.2 By Country
4.3 By Indication
4.4 By Phase
4.5 By Priority Status
5. GLOBAL CRISPR-CAS9 THERAPY CLINICAL TRIALS BY COMPANY, COUNTY, INDICATION & PHASE
5.1 Research
5.2 Preclinical
5.3 Phase I
5.4 Phase I/II
5.5 Phase II
6. APPROVED CRISPR - CAS9 THERAPY: CASGEVY (EXAGAMGLOGENE AUTOTEMCEL) THERAPY CLINICAL INSIGHT
7. APPROVED CRISPR-CAS9 THERAPY - OVERVIEW, PRICING & DOSING ANALYSIS
7.1 Casgevy (Exagamglogene Autotemcel)
7.1.1 Overview
7.1.2 Pricing & Dosing
8. GLOBAL CRISPR-CAS9 THERAPY CURRENT MARKET TREND & DEVELOPMENTS
8.1 Current Market Outline
8.2 Future Market Outlook
9. CRISPR-CAS9 THERAPY MARKET TREND ANALYSIS BY REGION
9.1 US
9.2 UK
9.3 EU
9.4 China
9.5 Japan
9.6 South Korea
10. CRISPR-CAS9 THERAPY MARKET OPPORTUNITIES & CLINICAL TRIAL STATISTICS: BY INDICATIONS
10.1 Inherited Blood Disorders
10.2 Genetic Disorders
10.3 Cancer
10.4 Autoimmune & Inflammatory Disorders
10.5 Microbial Infections
10.6 Cardiovascular Illnesses
10.7 Eye Disorders, Brain Diseases, Metabolic Illness & Other Conditions
11. COMBINATION APPROACHES FOR CRISPR-CAS9 THERAPY
12. PLATFORMS FOR ADVANCING CRISPR-CAS9 THERAPY
12.1 CRISPR-GNDM Modalis Therapeutics Platform
12.2 Intellia Therapeutics - Modular Platform
12.3 Editas Medicine CRISPR Gene Editing Platform
12.4 CRISPR-Cas9 Genome Editing Technology – ERS Genomics
12.5 CRISTARS Gene Editing Technology Innovation Platform- BRL Medicine
12.6 Gene Editing-BDmRNA Platform Shanghai BDgene
12.7 Kamau Therapeutics Next-Generation Gene Editing Platform
12.8 Excision BioTherapeutics CRISPR Gene Editing Technology
13. GLOBAL CRISPR-CAS9 THERAPY MARKET DYNAMICS
13.1 Market Drivers
13.2 Market Achilles Heels
14. COMPETITIVE LANDSCAPE
14.1 4D Molecular Therapeutics
14.2 Arbor Biotechnologies
14.3 ASC Therapeutics
14.4 C4U Corporation
14.5 Casebia Therapeutics
14.6 CRISPR Therapeutics
14.7 Editas Medicine
14.8 Intellia Therapeutics
14.9 Nkarta Therapeutics
14.10 Vertex Pharmaceuticals
Table 1-1: Global - Approved CRISPR-Cas9 Therapies
Table 9-1: US – Ongoing CRISPR-Cas9 Clinical Trials
Table 9-2: CRISPR-Cas9 Candidates Granted FDA Designations
Table 9-3: EU – Ongoing Clinical Trials for CRISPR/Cas9-based Therapeutics, July’2024
Table 9-4: ERS Genomics – Collaborations
Table 10-1: Ongoing CRISPR-Cas9 Clinical Trials for Inherited Blood Disorders
Table 10-2: Ongoing CRISPR-Cas9 Clinical Trials for Cancer Disorders
Table 10-3: Collaboration Deals For Cancer CRISPR-Cas9 Therapy, July 2024
Table 11-1: Ongoing Preclinical & Clinical trials for Combination of CRISPR-Cas9 Therapy
